Shares of hVIVO plc (LON:HVO – Get Free Report) were down 6.8% during mid-day trading on Thursday . The stock traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Price Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock has a fifty day simple moving average of GBX 23.20 and a 200-day simple moving average of GBX 26.66. The company has a market capitalization of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
- Five stocks we like better than hVIVO
- The 3 Best Fintech Stocks to Buy Now
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- ESG Stocks, What Investors Should Know
- Nebius Group: The Rising Star in AI Infrastructure
- Which Wall Street Analysts are the Most Accurate?
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
